Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.

Media type: E-Article

Title: Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party

Contributor: Martinelli, Giovanni; Palandri, Francesca; Iacobucci, Ilaria; Bassi, Simona; Castagnetti, Fausto; Amabile, Marilina; Cilloni, Daniela; Poerio, Angela; Soverini, Simona; Rege-Cambrin, Giovanna; Iuliano, Franco; Alimena, Giuliana; Latagliata, Roberto; Testoni, Nicoletta; Pane, Fabrizio; Saglio, Giuseppe; Rosti, Gianantonio; Baccarani, Michele

imprint: American Society of Hematology, 2006

Language: English

DOI: 10.1182/blood.v108.11.4805.4805

ISSN: 0006-4971; 1528-0020

Keywords: Cell Biology ; Hematology ; Immunology ; Biochemistry

Origination:

Footnote:

Description: Abstract To assess the effect of age on response and compliance we performed a sub-analysis within a phase II trial of the GIMEMA CMLWorking Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, we identified: 226/284 (80%) younger patients (below 65 years) and 58/284 (20%) older patients (above 65 years) before starting imatinib. Responses (hematologic and cytogenetic) were lower in older age group but progression free survival and overall survival probabilities (median observation time 3 years) were the same. Moreover, among complete cytogenetic responders, no differences were found in the level of molecular response between the 2 age groups. As probably expected, older patients experienced more adverse events (AEs), both hematologic and non-hematologic: this worsen compliance, however, did not prevent a long term outcome similar to younger ones. CML

Access State: Open Access

Search in field:

Recently searched for: